(NASDAQ: INAB) In8bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
In8bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast INAB's revenue for 2027 to be $36,363,133, with the lowest INAB revenue forecast at $36,363,133, and the highest INAB revenue forecast at $36,363,133. On average, 1 Wall Street analysts forecast INAB's revenue for 2028 to be $357,593,508, with the lowest INAB revenue forecast at $357,593,508, and the highest INAB revenue forecast at $357,593,508.
In 2029, INAB is forecast to generate $656,715,461 in revenue, with the lowest revenue forecast at $656,715,461 and the highest revenue forecast at $656,715,461.